Simulations Plus Inc. reported a net income of $3.6 million [1] for its fiscal third quarter of 2026.
The results indicate a return to profitability for the company, which provides software and services to the biopharmaceutical industry. This growth suggests a strengthening demand for simulation-based modeling in drug development.
The company reported a seven percent revenue gain [2] during the period. This increase was primarily driven by a 20% growth in services [3]. Based in Research Triangle Park, N.C., the company presented these findings during an earnings call on Thursday.
Financial analysts noted that the company exceeded expectations for the quarter. One analyst said that Simulations Plus crushed EPS expectations by 29% and returned to GAAP profitability [4].
The company's performance reflects a broader trend of integrating digital simulations into the pharmaceutical pipeline to reduce the cost and time of clinical trials. The 20% increase in services [3] highlights a shift toward specialized consulting, and technical support to accompany its software offerings.
“Simulations Plus crushed EPS expectations by 29%”
The return to GAAP profitability and the significant growth in the services sector indicate that Simulations Plus is successfully diversifying its revenue streams beyond software licensing. By expanding its service offerings, the company is becoming more deeply embedded in the regulatory and developmental workflows of biopharmaceutical firms, creating more sustainable long-term growth.
